GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Lushang Freda Pharmaceutical Co Ltd (SHSE:600223) » Definitions » Research & Development

Lushang Freda Pharmaceutical Co (SHSE:600223) Research & Development : ¥156 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lushang Freda Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lushang Freda Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was ¥33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥156 Mil.


Lushang Freda Pharmaceutical Co Research & Development Historical Data

The historical data trend for Lushang Freda Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lushang Freda Pharmaceutical Co Research & Development Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.07 77.17 118.75 133.92 153.37

Lushang Freda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.88 34.89 35.70 52.89 32.89

Lushang Freda Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lushang Freda Pharmaceutical Co  (SHSE:600223) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Lushang Freda Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Traded in Other Exchanges
N/A
Address
No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
Executives
Li Hang senior management
Yin Wei Directors, senior managers
Shao Zhao Wei senior management
Wang Zhong Wu senior management
Dong Hong Lin Director
Zhou Hong Bo senior management
Li Lu senior management
Liu Zeng Wei senior management
Zhang Quan Li senior management
Xu Tao senior management
Ju Hai Bo Director
Zhao Xi Liang Director
Pi Xi Cai Supervisors

Lushang Freda Pharmaceutical Co (SHSE:600223) Headlines

No Headlines